Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Thomas
T
Cuisset
Jacques
J
Quilici
Jean-Louis
JL
Bonnet
Marie-Christine
MC
Alessi
D054058:Acute Coronary Syndrome / Q000628:therapy*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D010879:Piperazines / Q000009:adverse effects*; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013876:Thiophenes / Q000009:adverse effects*; D013988:Ticlopidine / Q000031:analogs & derivatives*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D013988:Ticlopidine